Skip Navigation LinksHome > August 2014 - Volume 26 - Issue 4 > Chemotherapy in the treatment of metastatic, persistent, and...
Text sizing:
A
A
A
Current Opinion in Obstetrics & Gynecology:
doi: 10.1097/GCO.0000000000000042
SPECIAL COMMENTARY: Edited by Anne Rodriguez

Chemotherapy in the treatment of metastatic, persistent, and recurrent cervical cancer

Eskander, Ramez N.; Tewari, Krishnansu S.

Collapse Box

Abstract

Purpose of review

Patients with cervical cancer represent a vulnerable population with limited chemotherapeutic options. This year, two large trials focusing on detection/screening and treatment of advanced stage cervical cancer were featured in the opening plenary session of the American Society of Clinical Oncology Annual Meeting. As such, a review of the evolution of chemotherapy in the treatment of this disease is warranted.

Recent findings

Following the establishment of cisplatin as an effective single-agent regimen in patients with advanced stage, recurrent, or persistent cervical cancer, several platinum-containing combinations were studied. Ultimately, the adoption of cisplatin chemosensitizing radiation resulted in relative ‘cisplatin resistance’ and the concept of nonplatinum doublets emerged as an active area of investigation.

Summary

In an era of biologics, combined therapy with cytotoxic drugs and molecular targeted agents, as well as the use of nonplatinum doublets, represent an exciting area yet to be fully explored.

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.